Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) is a genomic medicine company whose news flow centers on clinical data, regulatory interactions, collaborations and financial updates across its neurology‑focused pipeline. Company announcements emphasize investigational programs in Fabry disease, chronic neuropathic pain and prion disease, along with progress in its zinc finger epigenetic regulation and AAV capsid platforms.
A major theme in recent SGMO news is the development of isaralgagene civaparvovec (ST‑920), a wholly owned investigational gene therapy for adults with Fabry disease. Press releases detail topline and updated results from the registrational Phase 1/2 STAAR study, including positive mean annualized estimated glomerular filtration rate (eGFR) slopes at 52 and 104 weeks, stability of cardiac endpoints, biomarker trends and quality‑of‑life measures. Regulatory milestones, such as FDA agreement to use eGFR slope as an endpoint for an accelerated approval pathway and acceptance of a rolling Biologics License Application (BLA) submission, are also key subjects.
Investors following SGMO news can also track developments in the Phase 1/2 STAND study of ST‑503 for intractable pain due to small fiber neuropathy, including FDA Fast Track Designation, site activation and recruitment updates. Additional releases describe preclinical and regulatory progress for ST‑506 in prion disease, as well as business development activities like the capsid license agreement with Eli Lilly and Company and other collaboration‑related revenues.
Quarterly earnings releases and conference call announcements provide context on Sangamo’s operating expenses, cash position and strategic focus on a neurology‑oriented genomic medicine business. For readers interested in SGMO, this news page aggregates these clinical, regulatory, partnership and financial disclosures in one place, making it easier to follow the company’s reported milestones over time.
Sangamo Therapeutics (Nasdaq: SGMO) reported significant advancements in its clinical programs during Q1 2022, including the first patient dosed in a kidney transplant rejection study using CAR-Treg therapy. With a net loss of $44.0 million, or $0.30 per share, the company saw a revenue increase to $28.2 million, attributed to collaborations with Novartis, Biogen, and Sanofi. The company maintains an outlook for total operating expenses between $320 million and $350 million for 2022, with a cash position of $400.3 million as of March 31, 2022, ensuring continued operational support.
Sangamo Therapeutics (NASDAQ: SGMO) announced acceptance of eight abstracts for presentation at the 25th ASGCT Annual Meeting, taking place May 16-19, 2022, in Washington, D.C. Presentations will highlight advancements in Sangamo's genomic engineering platform, including a study on AAV capsids for CNS delivery, which address challenges posed by the blood-brain barrier. Notable studies include presentations on base-editing and CAR-T cell engineering. Sangamo aims to showcase its innovative research, contributing to transformative medicine for patients with unmet needs.
Sangamo Therapeutics (NASDAQ: SGMO) announced the release of its first quarter 2022 financial results, scheduled for May 5, 2022, after market close. A conference call will be held at 4:30 p.m. ET to discuss the results and provide business updates, accessible via telephone and webcast. Domestic callers can dial (877) 377-7553, while international participants may call (678) 894-3968, using conference ID 3090098. A replay will be available for one week following the event. For more information, visit the Sangamo Therapeutics website.
Sangamo Therapeutics (Nasdaq: SGMO) announced participation in three upcoming investor conferences. The events are:
- Bank of America Securities Conference on May 11 at 3:00 p.m. ET
- RBC Global Healthcare Conference on May 18 at 3:05 p.m. ET
- H.C. Wainwright Global Investment Conference on May 24 at 7:00 a.m. ET
Access to presentations will be available on the Sangamo Therapeutics website under the Investors and Media section.
Sangamo Therapeutics (SGMO) announced the dosing of the first patient in its Phase 1/2 STEADFAST clinical study for TX200, an innovative CAR-Treg cell therapy aimed at preventing immune-mediated rejection in HLA-A2 mismatched kidney transplants. This represents a significant milestone in genomic medicine, with hopes of reducing the need for lifelong immunosuppressants. The study aims to assess TX200's safety and effectiveness, marking a potential breakthrough in treating patients receiving kidneys from living donors.
Sangamo Therapeutics, a genomic medicine company (NASDAQ: SGMO), will participate in three upcoming investor conferences in March 2022. These include the Cowen 42nd Annual Health Care Conference on March 7 at 12:50 p.m. ET, the Barclays Global Healthcare Conference on March 17 at 9:00 a.m. ET, and the H.C. Wainwright & Co. Gene Editing and Therapy Conference on March 30 at 7:00 a.m. ET. Presentations will be accessible via the company’s website in the Investors and Media section post-event.
For more details about Sangamo's innovative genomic medicines pipeline, visit www.sangamo.com.
Sangamo Therapeutics (SGMO) reported its financial results for Q4 and full year 2021, highlighting advances in genomic medicines across multiple therapeutic areas. The company noted ongoing developments in its gene therapy candidates for Fabry disease and sickle cell disease, alongside its hemophilia A collaboration with Pfizer. However, the firm reported a consolidated net loss of $178.3 million for 2021, compared to a loss of $121.1 million in 2020. Cash, cash equivalents, and marketable securities decreased to $464.7 million by year-end. 2022 operating expense guidance is set between $320 million and $350 million.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced the release date for its fourth quarter and full year 2021 financial results, scheduled for February 24, 2022, after market close. Following this, a conference call will take place at 4:30 p.m. ET to discuss the results and provide business updates. The call can be accessed via telephone or webcast. Details for call-in numbers and a link to the live webcast are available on the company's website. Sangamo focuses on developing genomic medicines for diseases lacking adequate treatment options.
Sangamo Therapeutics has reported updated results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. As of November 9, 2021, the treatment was well tolerated across five patients, with α-Gal A activity significantly elevated in four patients (3-15 times above normal). The fifth patient in the third cohort showed mean normal levels at week 2. Notably, there were no serious adverse events. Sangamo plans to advance to Phase 3 following the completion of the current study, with further results expected throughout 2022.
Sangamo Therapeutics, Inc. announced that Sanofi will transition its rights for SAR445136, a gene-edited cell therapy for sickle cell disease, back to Sangamo in the first half of 2022. This change follows Sanofi's decision to terminate their collaboration, citing a shift in strategy. The Phase 1/2 PRECIZN-1 study of SAR445136 is expected to finish as planned, with final patient dosing anticipated in Q3 2022. Preliminary data showed no treatment-related adverse events, and treated patients did not require blood transfusions post-engraftment.